400-859-2883
Your location:Home >News center >Industry News

Industry News

02-192024

Summary of ADC Targets for Breast Cancer

Some new ADC antigen targets for breast cancer, including Nectin-4, HER3, tissue factor (TF), FRα, LIV-1, ROR1-2, and B7-H4, etc.

Summary of ADC Targets for Breast Cancer
01-252024

Pro-xylane – Powerful Cosmetic Ingredien…

Pro-xylane, also known as hydroxyethyl tetrahydropyrantriol, is an anti-aging active substance that promotes the synthesis of collagen.

Pro-xylane – Powerful Cosmetic Ingredient
01-112024

Advances in Nonalcoholic Fatty Liver Dise…

The U.S. FDA has not yet approved any drugs for NASH treatment. The search for an effective and safe treatment for NASH is urgent.

Advances in Nonalcoholic Fatty Liver Disease (NAFLD) Treatment
12-262023

Molecular glues: Current Satus and Future…

What are molecular glues? What are advantages of molecular glues over PROTACs? And list of molecular glues approvals and in clinic trails.

Molecular glues: Current Satus and Future Development
12-142023

Summary of GLP-1 Drug Long-Acting Strateg…

To address the issue of a short half-life, various methods and strategies have been employed from two perspectives: enhancing tolerance to DPP-4 enzyme and reducing in vivo clearance.

Summary of GLP-1 Drug Long-Acting Strategies
11-182023

List of FDA Approved PEGylated Drugs Up t…

History of PEGylated drugs, list of FDA approved PEGylated drugs, advantages and challenges of PEGylation.

List of FDA Approved PEGylated Drugs Up to 2023
11-102023

Summary of ADCs in Clinical Phase 3

Summary of FDA approved ADCs and ADCs in clinical phase 3.

Summary of ADCs in Clinical Phase 3
10-272023

Classification of Anticoagulant Drugs

4 types of anticoagulants: Vitamin K antagonists (VKA), indirect thrombin inhibitors, direct thrombin inhibitors and factor Xa inhibitors. and Representative Drugs

Classification of Anticoagulant Drugs
10-132023

Semaglutide Indication Opportunity: From …

On October 10, 2023, Novo Nordisk announced the early termination of a Phase 3 clinical trial of semaglutide for the treatment of patients with kidney injury and chronic kidney disease who ha…

Semaglutide Indication Opportunity: From CDK, HFpEF to Alzheimer's disease
09-222023

Nectin-4 ADCs for Cancer Treatment

At present, only one Nectin-4 ADC drug, Padcev (enfortumab vedotin), has been approved for marketing for the second-line treatment of patients with uroepithelial cancer.

Nectin-4 ADCs for Cancer Treatment